Should I buy or sell PolyPid stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYPD shares. View PYPD analyst ratings or view top-rated stocks .

How have PYPD shares performed in 2024?

PolyPid's stock was trading at $3.80 on January 1st, 2024. Since then, PYPD shares have increased by 13.2% and is now trading at $4.30. View the best growth stocks for 2024 here .

Are investors shorting PolyPid?

PolyPid saw a decrease in short interest in March. As of March 31st, there was short interest totaling 3,300 shares, a decrease of 17.5% from the March 15th total of 4,000 shares. Based on an average daily volume of 4,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the shares of the stock are sold short. View PolyPid's Short Interest .

When is PolyPid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our PYPD earnings forecast .

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80.

When did PolyPid's stock split?

Shares of PolyPid reverse split on the morning of Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD) , Moderna (MRNA) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , Cardinal Health (CAH) , Genocea Biosciences (GNCA) , LightPath Technologies (LPTH) , Stride (LRN) and Livongo Health (LVGO) .

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an IPO on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

→ The Next Nvidia? (From InvestorPlace) (Ad)

Free PYPD Stock Alerts

$4.30

-0.14 (-3.15%)

(As of 05:17 PM ET)

Compare

Today's Range: $4.30
▼
$4.50
50-Day Range: $4.25
▼
$6.92
52-Week Range: $3.57
▼
$13.50

Volume: 5,248 shs
Average Volume: 6,708 shs
Market Capitalization: $20.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get PolyPid alerts:

PolyPid MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.37% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.98
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($3.72) to ($2.37) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.29 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for PolyPid.

5.0

Short Interest

Percentage of Shares Shorted
0.37% of the float of PolyPid has been sold short.
Short Interest Ratio / Days to Cover
PolyPid has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in PolyPid has recently decreased by 17.50%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
PolyPid does not currently pay a dividend.
Dividend Growth
PolyPid does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PYPD.

3.3

News and Social Media Coverage

News Sentiment
PolyPid has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for PolyPid this week, compared to 1 article on an average week.
MarketBeat Follows
2 people have added PolyPid to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, PolyPid insiders have not sold or bought any company stock.
Percentage Held by Insiders
24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 26.47% of the stock of PolyPid is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for PolyPid are expected to grow in the coming year, from ($3.72) to ($2.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of PolyPid is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of PolyPid is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About PolyPid Stock (NASDAQ:PYPD)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PYPD Stock News Headlines

April 18, 2024 | finance.yahoo.com

PolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo Finance

April 15, 2024 | americanbankingnews.com

Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Declines By 17.5%

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 28, 2024 | globenewswire.com

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

February 19, 2024 | finance.yahoo.com

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

February 15, 2024 | finance.yahoo.com

PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript

February 14, 2024 | markets.businessinsider.com

Buy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market Positioning

February 14, 2024 | finanznachrichten.de

PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 14, 2024 | finance.yahoo.com

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 14, 2024 | globenewswire.com

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

February 12, 2024 | finanznachrichten.de

PolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

February 12, 2024 | finance.yahoo.com

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

January 31, 2024 | finance.yahoo.com

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

January 5, 2024 | msn.com

Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session

January 5, 2024 | msn.com

Cyclacel Pharmaceuticals, Angiodynamic among healthcare movers

January 4, 2024 | uk.finance.yahoo.com

PolyPid Ltd. (PYPD)

January 4, 2024 | msn.com

PolyPid looks to raise $16.2M through private placement

January 4, 2024 | finance.yahoo.com

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

November 12, 2023 | finance.yahoo.com

PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript

November 12, 2023 | investing.com

Earnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trial

November 8, 2023 | finance.yahoo.com

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

November 7, 2023 | benzinga.com

PolyPid's Earnings: A Preview

November 7, 2023 | finance.yahoo.com

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

November 1, 2023 | finance.yahoo.com

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

October 24, 2023 | msn.com

Barclays Maintains Polypid (PYPD) Equal-Weight Recommendation

October 19, 2023 | finance.yahoo.com

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

See More Headlines

Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/14/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:PYPD
CUSIP: N/A
CIK: 1611842
Web: www.polypid.com
Phone: 972-74-719-5700
Fax: N/A
Employees: 59
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($19.6823)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -450.37%
Return on Assets: -101.27%

Debt

Debt-to-Equity Ratio: 2.17
Current Ratio: 0.83
Quick Ratio: 0.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.27) per share
Price / Book: -3.50

Miscellaneous

Outstanding Shares: 4,800,000
Free Float: 3,612,000
Market Cap: $21.31 million
Optionable: Optionable
Beta: 1.41

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Ms. Dikla Czaczkes Akselbrad (Age 51)
CEO & Director
Comp: $347.88k
Mr. Jonny Missulawin (Age 37)
Chief Financial Officer
Comp: $186.96k
Ms. Dalit Hazan (Age 53)
Executive Vice President of R&D and Clinical & Regulatory Affairs
Comp: $272.38k
Mr. Ori Warshavsky (Age 46)
Chief Operating Officer - US
Comp: $340.89k
Ms. Maria Rubin
Vice President of Operations
Mr. Tal Vilnai
General Counsel & Corporate Secretary
Ms. Rivi Lev-ari
Vice President of Human Resource
Dr. Jean-Marc Hagai Pharm.D.
Chief Commercial Officer

Key Competitors

View All Competitors

PYPD Stock Analysis - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings or view top-rated stocks.
How have PYPD shares performed in 2024?: PolyPid's stock was trading at $3.80 on January 1st, 2024. Since then, PYPD shares have increased by 13.2% and is now trading at $4.30.
View the best growth stocks for 2024 here.
Are investors shorting PolyPid?: PolyPid saw a decrease in short interest in March. As of March 31st, there was short interest totaling 3,300 shares, a decrease of 17.5% from the March 15th total of 4,000 shares. Based on an average daily volume of 4,500 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the shares of the stock are sold short.
View PolyPid's Short Interest.
When is PolyPid's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PYPD earnings forecast.
How were PolyPid's earnings last quarter?: PolyPid Ltd. (NASDAQ:PYPD) posted its quarterly earnings data on Wednesday, February, 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80.

When did PolyPid's stock split?: Shares of PolyPid reverse split on the morning of Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
What other stocks do shareholders of PolyPid own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).
When did PolyPid IPO?: PolyPid (PYPD) raised $50 million in an IPO on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.
How do I buy shares of PolyPid?: Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYPD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial